Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
Douglas D. Fang(Zhejiang Hisun Pharmaceutical (China)), Yifan Zhai(Unknown)
Cited by 31
Related Papers
Activating <i>JAK1</i> mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
|Oncotarget|2015|49
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
|Clinical Cancer Research|2023|38